FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.

Autor: Milton CI; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Selfe J; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Aladowicz E; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Man SYK; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Bernauer C; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Missiaglia E; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Walters ZS; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Gatz SA; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Kelsey A; Department of Paediatric Histopathology, Manchester University NHS Foundation Trust, Royal Manchester Children's Hospital, UK., Generali M; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK., Box G; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Valenti M; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., de Haven-Brandon A; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Galiwango D; Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Hayes A; Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Clarke M; Glioma Team, Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Izquierdo E; Glioma Team, Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Gonzalez De Castro D; Molecular Haematology, Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Raynaud FI; Drug Metabolism and Pharmacokinetics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Kirkin V; Cancer Pharmacology and Stress Response Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Shipley JM; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK.

Publikováno v: Molecular oncology [Mol Oncol] 2022 Mar; Vol. 16 (6), pp. 1272-1289. Date of Electronic Publication: 2021 Dec 18.